July 7, 2026
- Notable Approval: FDA Approves New Treatment to Reduce Proteinuria in Adults with Primary Immunoglobulin A Nephropathy
July 1, 2026
- Public Notification: MAGNUM Brand products may be harmful due to hidden drug ingredients
- Final Guidance: Submitting Next-Generation Sequencing Data to the Division of Antiviral Products
This report displays final approvals and tentative approvals of original and supplemental applications for the two days beginning on the earliest date listed below. Some approvals may be added to the Drugs@FDA database after this time span. For comprehensive approval reports, please use the monthly "All Approvals" report on Drugs@FDA.
